Plural Nitrogens Nonionically Bonded Patents (Class 514/564)
  • Patent number: 10632091
    Abstract: Compositions of L-4-chlorokynurenine are provided, as are methods for the treatment of neurologica dyslinction.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: April 28, 2020
    Assignee: VISTAGEN THERAPEUTICS, INC.
    Inventors: H. Ralph Snodgrass, Allen E. Cato, Jack S. Hicklin
  • Patent number: 10617663
    Abstract: Compositions of L-4-chlorokynurenine are provided, as are methods for the treatment of neurological dysfunction.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: April 14, 2020
    Assignee: VISTAGEN THERAPEUTICS, INC.
    Inventors: H. Ralph Snodgrass, Allen E. Cato, Jack S. Hicklin
  • Patent number: 10464883
    Abstract: Novel compounds of formula (II) are disclosed. Compounds of formula (II) comprise ornithine derivatives or compounds that may metabolize to ornithine. Also disclosed are methods for the treatment of neurodegenerative diseases such as Alzheimer's Disease using compounds of formula (II).
    Type: Grant
    Filed: April 11, 2016
    Date of Patent: November 5, 2019
    Assignee: Resilio Therapeutics, LLC
    Inventors: Francis Xavier Tavares, Michael Peter Vitek
  • Patent number: 10428008
    Abstract: Nitroalkene non-steroidal anti-inflammatory compounds, pharmaceutical compositions thereof, and methods of treating inflammation related conditions.
    Type: Grant
    Filed: December 27, 2017
    Date of Patent: October 1, 2019
    Assignee: Institut Pasteur de Montevideo
    Inventors: Carlos Batthyány, Gloria Virginia López, Carlos Escande, Jorge Rodriguez Duarte, Williams Arturo Porcal Quinta, Rosina Dapueto Capuccio, Germán Adrian Galliussi López, María Pia Garat Nuñez, Paulina Invernizzi, Mariana Ingold, Lucia Colella
  • Patent number: 10265286
    Abstract: A method for administering citrulline to a patient during surgery without filtration of the hemolysis to reduce the uncoupling of eNOS enzyme dimer that leads to cardiopulmonary bypass-induced pulmonary injury.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: April 23, 2019
    Assignee: Vanderbilt University
    Inventors: Marshall L. Summar, Frederick W. Barr
  • Patent number: 10266482
    Abstract: [Problem] To provide a method for inducing a long-term memory in a subject in need thereof. [Solution to problem] A method for inducing a long-term memory, comprising a step of administering a compound represented by Formula I below, a pharmaceutically acceptable salt thereof or a solvate thereof to the subject.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: April 23, 2019
    Assignees: National University Corporation Tokyo Medical and Dental University, Sophia School Corporation
    Inventors: Atsuhiko Hattori, Yukihisa Matsumoto, Hiroyuki Kagechika, Hiroyuki Masuno, Atsuhiko Chiba, Hikaru Iwashita, Yusuke Maruyama
  • Patent number: 10098887
    Abstract: Inhibitors of retroviral propagation, methods of treatment and prevention of retroviral infections using the inhibitors, and pharmaceutical compositions including the inhibitors, are disclosed.
    Type: Grant
    Filed: November 3, 2015
    Date of Patent: October 16, 2018
    Assignee: Trana Discovery, Inc.
    Inventors: Richard H. Guenther, Jerzy R. Szewczyk
  • Patent number: 9993450
    Abstract: Compositions of L-4-chlorokynurenine are provided, as are methods for the treatment of neurological dysfunction.
    Type: Grant
    Filed: January 22, 2014
    Date of Patent: June 12, 2018
    Assignee: VISTAGEN THERAPEUTICS, INC.
    Inventors: H. Ralph Snodgrass, Allen E. Cato, Jack S. Hicklin
  • Patent number: 9993453
    Abstract: Compositions of L-4-chlorokynurenine are provided, as are methods for the treatment of neurological dysfunction.
    Type: Grant
    Filed: February 8, 2016
    Date of Patent: June 12, 2018
    Assignee: VISTAGEN THERAPEUTICS, INC.
    Inventors: H. Ralph Snodgrass, Allen E. Cato, Jack S. Hicklin
  • Patent number: 9895324
    Abstract: Halogenated diarylacetylenes, e.g., diarylacetylenes having at least one halo substituent in one aryl ring and an amine in the opposing aryl ring, can inhibit the proliferation of LS174T colon cancer cells through the inhibition of c-myc and induction of the cyclin-dependent kinase inhibitor-1 (i.e., p21(Wif1/Cip1)). Such compounds are useful as antineoplastic agents.
    Type: Grant
    Filed: March 25, 2015
    Date of Patent: February 20, 2018
    Assignee: University of Kentucky Research Foundation
    Inventors: Vitaliy M. Sviripa, Wen Zhang, Chunming Liu, David Watt
  • Patent number: 9663450
    Abstract: A method for the purification and preparation of melphalan that allows to obtain melphalan with purity higher than 99.5% is described.
    Type: Grant
    Filed: May 27, 2014
    Date of Patent: May 30, 2017
    Assignee: FARMABIOS S.P.A.
    Inventors: Claudio Gianluca Pozzoli, Valentina Canevari, Matteo Curti
  • Patent number: 9451767
    Abstract: The present invention relates to an aqueous composition comprising dicamba and a drift control agent; to a method for preparing a tank mix, which comprises the step of contacting water and said composition, and optionally further pesticides; to a method of controlling phytopathogenic fungi and/or undesired vegetation and/or unde-sired insect or mite attack and/or for regulating the growth of plants, wherein the composition is allowed to act on the respective pests, their environment or the plants to be protected from the respective pest, on the soil and/or on undesired plants and/or the crop plants and/or their environment; and finally to a use of the alkoxylate of the formula (I) as defined below for reducing the wind drift of an aqueous composition comprising a pesticide.
    Type: Grant
    Filed: June 11, 2013
    Date of Patent: September 27, 2016
    Assignee: BASF SE
    Inventors: Marc Nolte, Wen Xu, Steven Bowe, Maarten Staal, Terrance M. Cannan
  • Patent number: 9340483
    Abstract: The present invention relates to use of DHA analogs and their pharmaceutical compositions for treating ALS, by administering these compounds or pharmaceutical compositions to subjects in need thereof.
    Type: Grant
    Filed: February 15, 2013
    Date of Patent: May 17, 2016
    Assignee: ANIDA PHARMA INC.
    Inventor: Per Gjorstrup
  • Patent number: 9289380
    Abstract: A composition prepared for treating animals suffering from parasites which parasites are known to be susceptible to at least one of the avermectins, milbemycins or salicylanilides, comprises for example ivermectin in an amount of from 0.1 to 10%(w/v), a solvent selected from the group consisting of glycerol formal, propylene glycol, polyethylene glycol and combinations thereof, and a salicylanilide such as closantel in a required dosage amount for the animal to be treated, typically about 2.5 mg/kg live weight of the animal to be treated, a polymeric species selected from the group consisting of polyvinylpyrrolidone and polyoxypropylene/polyoxyethylene block copolymers, the said polymeric species improving the bioavailability of closantel to the extend that blood plasma levels of the said compound greater than about 20 ppm over period of treatment are achievable.
    Type: Grant
    Filed: February 12, 2003
    Date of Patent: March 22, 2016
    Assignee: Norbrook Laboratories Limited
    Inventors: William Blakely, Lillian Cromie, Sean Duffy
  • Patent number: 9121852
    Abstract: The present invention provides methods and kits a) for predicting colorectal cancer patient survival, as well as the survival of patients harboring other invasive cancers where cellular proliferation and carcinogenesis is linked, in part, to high levels of ODC activity and increased cellular polyamine contents, and b) for selecting the corresponding treatment options for such patients based on the allelic nucleotide sequence or SNP at position +316 of the ODC1 promoter gene as well as cancer treatment methods, in each case, which include the determination of the ODC1 promoter +316 position genotype, as a means to guide treatment selection.
    Type: Grant
    Filed: December 10, 2012
    Date of Patent: September 1, 2015
    Assignees: ARIZONA BOARD OF REGENTS ON BEHALF OF UNIVERSITY OF ARIZONA, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION
    Inventors: Eugene W. Gerner, Jason A. Zell, Christine E. McLaren, Frank L. Meyskens, Jr., Hoda Anton-Culver, Patricia A. Thompson
  • Patent number: 9040582
    Abstract: A relaxation formulation structured to induce a deep state of relaxation in a person comprises amounts of tryptophan, melatonin, vitamin B3, and vitamin B6. Another relaxation formulation also includes an amount of tyrosine, and yet another formulation includes an amount of vitamin B12. At least one embodiment of a relaxation formula comprises a physiologically effective amount of gamma-aminobutyric acid (“GABA”). A delivery system is provided to facilitate administration of the relaxation formulation to a person. The delivery system may include an edible high carbohydrate matrix, such as a chocolate brownie. Alternatively, the delivery system may comprise an inert vaporizable compound to allow the components of the relaxation formulation to be inhaled directly into the lungs of a person. Other delivery systems include an aqueous sublingual spray and a beverage.
    Type: Grant
    Filed: May 4, 2012
    Date of Patent: May 26, 2015
    Inventor: Raymond M. Keller
  • Publication number: 20150132408
    Abstract: The present invention provides sorafenib analogs for use in a method of treating a disease mediated by p21, said method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula I. The present invention also provides methods of inhibiting p21 in a cell comprising contacting the cell with an effective amount of a compound of formula I.
    Type: Application
    Filed: June 20, 2013
    Publication date: May 14, 2015
    Inventors: Robert H. Weiss, Bruce D. Hammock, Hiromi Inoue, Sung Hee Hwang
  • Patent number: 9029401
    Abstract: The present invention provides compounds for the inhibition of soluble epoxide hydrolase and associated disease conditions.
    Type: Grant
    Filed: February 14, 2012
    Date of Patent: May 12, 2015
    Assignee: The Regents of the University of California
    Inventors: Bruce D. Hammock, Sung Hee Hwang, Aaron T. Wecksler, Christophe Morisseau
  • Publication number: 20150126527
    Abstract: The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor.
    Type: Application
    Filed: October 9, 2014
    Publication date: May 7, 2015
    Inventors: Thuy-Anh Tran, Weichao Chen, Bryan A. Kramer, Abu J.M. Sadeque, Anna Shifrina, Young-Jun Shin, Pureza Vallar, Ning Zou
  • Publication number: 20150080382
    Abstract: This invention is directed to compounds of formula (I): where r, q, R, R2, R3, R4, R5a, R5b, R5c, R6a, R6b, R6c, R7, R8, and R9 are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A4 hydrolase inhibitors and therefore useful in treating inflammatory disorders. Pharmaceutical compositions comprising the compounds of the invention and methods of preparing the compounds of the invention are also disclosed.
    Type: Application
    Filed: June 24, 2014
    Publication date: March 19, 2015
    Inventors: Damian O. Arnaiz, Greg Brown, Emmanuel Claret, Arwed Cleve, David Davey, William Guilford, Seock-Kyu Khim, Thomas Kirkland, Monica J. Kochanny, Amy Liang, David Light, John Parkinson, Guo Ping Wei, Bin Ye
  • Patent number: 8980868
    Abstract: Novel solution complexes of zoledronic acid are described which give rise to improved properties of zoledronic acid. The invention includes aqueous solution and molecular complexes of zoledronic acid with and optical isomers of asparagine, histidine, arginine and proline as well as pharmaceutical complexes containing them and methods of treatment using them.
    Type: Grant
    Filed: July 30, 2010
    Date of Patent: March 17, 2015
    Assignee: Thar Pharmaceuticals, Inc.
    Inventors: Mazen Hanna, Ning Shan, Miranda Cheney, David Weyna
  • Publication number: 20150031635
    Abstract: Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise a phenolic opioid prodrug that provides enzymatically-controlled release of a phenolic opioid, and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the phenolic opioid from the prodrug so as to attenuate enzymatic cleavage of the prodrug.
    Type: Application
    Filed: June 30, 2014
    Publication date: January 29, 2015
    Inventors: Thomas E. Jenkins, Julie D. Seroogy, Jonathan W. Wray
  • Publication number: 20150025147
    Abstract: An agent for secreting ghrelin, comprising ornithine or a salt thereof as an active ingredient, an agent for enhancing eating activity, comprising ornithine or a salt thereof as an active ingredient, and an agent for enhancing gastrointestinal activity, comprising ornithine or a salt thereof as an active ingredient.
    Type: Application
    Filed: March 1, 2013
    Publication date: January 22, 2015
    Inventors: Kousaku Ohinata, Yee Yin Ho, Takafumi Mizushige, Kentaro Kaneko, Saori Akizuki, Koji Morishita
  • Publication number: 20150017267
    Abstract: The present invention relates to the prevention, reduction, inhibition and reversal of pain and inflammation in a non-human mammal by administration of an inhibitor of soluble epoxide hydrolase, as sole active agent or co-administered with other active agents.
    Type: Application
    Filed: March 5, 2013
    Publication date: January 15, 2015
    Applicant: The Regents of the University of California
    Inventors: Alonso G.P. Guedes, Bruce D. Hammock, Christophe Morisseau
  • Patent number: 8933267
    Abstract: The present invention relates to a compound according to formula I in particular as anti-ulcer agent and/or anti-Helicobacter pylori agent, wherein R1 is selected from linear or branched C1-C6 alkyl, H, thioether and benzyl, and R2 is selected from linear or branched C1-C10 alkanediyl and pharmaceutical compositions thereof.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: January 13, 2015
    Assignee: King Saud University
    Inventors: Amani S. Awaad, Reham Moustafa El-Meligy, Ahmed M. Alafeefy
  • Publication number: 20140371272
    Abstract: The invention provides compounds of formula (I) or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula (I) and therapeutic methods for treating cancer or treating autoimmune diseases or preventing transplant rejection using compounds of formula (I).
    Type: Application
    Filed: January 18, 2013
    Publication date: December 18, 2014
    Inventors: Venkatram R. Mereddy, Lester R. Drewes, Mohammed Abrar Alam, Sravan K. Jonnalagadda, Shirisha Gurrapu
  • Patent number: 8883131
    Abstract: A synergistic composition, or the use of that composition in the manufacture of a medicament, or a method of treatment including the use of that composition, for the treatment of hair loss and baldness, for combined, sequential or simultaneous administration, in any form, via any biological route. In its optimal embodiment the composition consists, in the form of a lotion: 1600-2400 IU/mL Vitamin A Palmitate, 0.64%-0.96% Thiamine Hydrochloride, 0.64%-0.96% Pyridoxine Hydrochloride, 4.8%-7.2% Niacinamide, 2.85%-5.2% D-Panthenol, 1.6%-2.4% L-Arginine, 3.6%-4.4% Methyl Sulphonyl Methane (MSM), 0.08%-0.12% Ginger Oil, 0.08%-0.12% Cinnamon Oil, 0.0996%-0.1494% Oleoresin Capsicum, 1.3%-1.95% Magnesium, 2.4%-3.6% Zinc, 0.192%-0.288% Manganese, 2.6%-3.9% Urea, 2.4%-3.6% Sodium Glycerophosphate, 4.8%-7.2% L-Lysine HCl, plus Preservatives, Co-solvent (Propylene Glycol), Fragrances, Anti-Oxidant, Cooling agent (Menthol), Emulsifier, and Vehicle (Purified water).
    Type: Grant
    Filed: October 26, 2010
    Date of Patent: November 11, 2014
    Inventors: Robert Peter Taylor, Kartar Singh Lalvani, Ajit Lalvani
  • Publication number: 20140329902
    Abstract: A blood coagulating device can include an absorbent body; and a hemostatic lysine composition associated with the body. The body can have a cylindrical or conical member having a first end having the hemostatic composition, the first end being configured for insertion into a nasal passageway. A method for coagulating blood can include providing a powdered hemostatic lysine composition; and applying the powdered hemostatic lysine composition to blood so as to cause the blood to coagulate and form a clot. The coagulation can occur in a nasal passageway away from a blood vessel. The method can include providing at least one absorbent member having the powdered hemostatic lysine composition; and applying the at least one absorbent member to the blood so that the powdered hemostatic lysine composition causes the blood to coagulate and clot.
    Type: Application
    Filed: May 2, 2014
    Publication date: November 6, 2014
    Applicant: Park City Bio, LLC
    Inventors: Jonathan M. Benns, Matthew C. Lawyer
  • Publication number: 20140322152
    Abstract: The present invention generally relates to a water-in-oil emulsion comprising at least one oil-soluble polar modified polymer and at least one polylysine, wherein the emulsion has a high water content.
    Type: Application
    Filed: October 1, 2012
    Publication date: October 30, 2014
    Applicant: L'OREAL
    Inventors: Mikhail Motornov, Hy Si Bui, Jean-Thierry Simonnet, Christopher Pang
  • Publication number: 20140314850
    Abstract: The present application relates to functionalized nanodiamonds, to complexes comprising a functionalized nanodiamond reversibly bound to a nucleic acid and to compositions comprising such functionalized nanodiamonds and complexes. In particular, the functionalized nanodiamonds comprise at least one naturally occurring basic amino acid, or analogs or derivatives thereof, covalently linked to a nanodiamond. The present application also includes methods and uses of the complexes and compositions, for example for delivering a nucleic acid to a cell.
    Type: Application
    Filed: April 17, 2014
    Publication date: October 23, 2014
    Applicant: University of Saskatchewan
    Inventors: Ildiko Badea, Ronald Verrall, Jackson M. Chitanda, Randeep Kaur, Saniya Alwani
  • Publication number: 20140294796
    Abstract: The disclosure provides compositions and methods relating to aromatic-cationic peptides. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof. For example, the peptides may be administered to subjects in need of a mitochondrial-targeted antioxidant.
    Type: Application
    Filed: December 5, 2012
    Publication date: October 2, 2014
    Inventors: D. Travis Wilson, Marc W. Andersen, Elizabeth Mead
  • Publication number: 20140286931
    Abstract: The present invention relates to new biphenyl-3-carboxylic acid modulators of beta-3-adrenoceptor activity, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: June 5, 2014
    Publication date: September 25, 2014
    Inventor: Chengzhi Zhang
  • Publication number: 20140256716
    Abstract: The invention relates to the use of C16-C18-carboxylic acid dibutylamides in agrochemical formulations, agrochemical formulations which comprise such compounds and the use as tank mix additives.
    Type: Application
    Filed: August 10, 2012
    Publication date: September 11, 2014
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Peter Baur, Martin Steinbeck, Ingo Wetcholowsky, Thomas Auler, Alison Daniels, Rolf Pontzen
  • Patent number: 8829049
    Abstract: The use of cubebin, dibenzylbutyrolactolic lignan, its semi-synthetic and synthetic derivatives for the treatment of erectile dysfunction is shown and disclosed.
    Type: Grant
    Filed: December 21, 2009
    Date of Patent: September 9, 2014
    Assignee: ACEF S.A.
    Inventors: Sérgio Albuquerque, Jairo Kenupp Bastos, Paulo Sérgio Calefi, Katia Jorge Ciuffi, Wilson Roberto Cunha, Rosangela da Silva de Laurentiz, Rodrigo Lucarini, Eduardo José Nassar, Ademar Alves da Silva Filho, Márcio Luís Andrade e Silva
  • Patent number: 8815917
    Abstract: Described herein is the DP2 antagonist [2?-(3-benzyl-1-ethyl-ureidomethyl)-6-methoxy-4?-trifluoromethyl-biphenyl-3-yl]-acetic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the DP2 antagonist, or a pharmaceutically acceptable salt thereof. Also described herein are pharmaceutical compositions suitable for administration to a mammal that include the DP2 antagonist, or a pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating respiratory diseases or conditions, allergic diseases or conditions, inflammatory diseases or conditions, as well as other prostaglandin D2-dependent or prostaglandin D2-mediated diseases or conditions.
    Type: Grant
    Filed: July 29, 2010
    Date of Patent: August 26, 2014
    Assignee: Panmira Pharmaceuticals, LLC
    Inventors: Jason Edward Brittain, Brian Andrew Stearns, Christopher David King, Kevin Ross Holme
  • Publication number: 20140235562
    Abstract: A method of treating an ocular disorder in a subject includes administering to the subject a therapeutically effective amount of an agent that modulates at least one target in a signaling cascade associated with light induced retinal degeneration, aberrant all-trans-retinal accumulation, and/or generation of reactive oxygen species (ROS).
    Type: Application
    Filed: April 25, 2014
    Publication date: August 21, 2014
    Inventors: Krzysztof Palczewski, Yu Chen
  • Publication number: 20140228296
    Abstract: The present invention relates to the discovery that an increased fraction of albumin is carbamylated in patients suffering from kidney disease (e.g., end-stage renal disease) and that the fraction of carbamylated albumin is also correlated with increased disease severity, particularly risk of mortality. The present invention also relates to the discovery that free amino acids can reduce carbamylation of albumin. Based on these discoveries the present invention provides diagnostic and prognostic methods for patients suffering from, or suspected of suffering from kidney disease. The invention also provides methods for treating kidney disease by administration of a compound or composition that reduced protein carbamylation, such as free amino acids or dipeptides.
    Type: Application
    Filed: July 13, 2012
    Publication date: August 14, 2014
    Applicant: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Anders H. Berg, S. Ananth Karumanchi, Ravi I. Thadhani
  • Patent number: 8802162
    Abstract: L-citrulline for treatment of endothelial dysfunction and in particular of erectile dysfunction and a pharmaceutical composition comprising L-citrulline in combination with one or more substances selected from the group consisting of pycnogenol, aqueous extract of Viscum album, NADPH, tetrahydrobiopterin, folic acid and mixtures thereof.
    Type: Grant
    Filed: March 10, 2009
    Date of Patent: August 12, 2014
    Assignee: Androsystems S.R.L.
    Inventor: Ermanno Greco
  • Publication number: 20140221488
    Abstract: The present invention is directed to pharmaceutical compositions comprising melphalan and a cyclodextrin derivative, and methods of making and using the same.
    Type: Application
    Filed: December 16, 2013
    Publication date: August 7, 2014
    Applicant: CYDEX PHARMACEUTICALS, INC.
    Inventors: James D. Pipkin, Stephen G. Machatha
  • Patent number: 8796336
    Abstract: The present invention is directed generally to protecting cells, tissues and organs against the damaging effects of ionizing or other damaging agents associated with radiation or chemotherapy, or degenerative diseases or processes of various organs that elicit the production of free radicals or oxidants such as peroxides, superoxide anions, hydroxyl radicals or nitric oxides, or heavy metal cations. More particularly, the present invention is concerned with methoxypolyethylene glycol chelate methyl esters that are useful as protectors against tissue damage by penetrating the cell membrane to donate electrons to free radical oxidants and remove heavy metals that may react with peroxides to produce the reactive hydroxyl radical, or remove Ca++ that may be released from organelles. These chelate esters will also have utility in reducing intraocular pressure in glaucoma patients.
    Type: Grant
    Filed: July 22, 2011
    Date of Patent: August 5, 2014
    Assignee: Eastern Virginia Medical School
    Inventors: Karl A. Schellenberg, Frank A. Lattanzio, James Shaeffer
  • Publication number: 20140213650
    Abstract: The present disclosure is directed to pharmaceutical compositions comprising a nitrogen mustard and a cyclodextrin derivative, and methods of making and using the same.
    Type: Application
    Filed: March 28, 2014
    Publication date: July 31, 2014
    Applicant: CYDEX PHARMACEUTICALS, INC.
    Inventors: James D. Pipkin, Stephen G. Machatha
  • Patent number: 8785497
    Abstract: The present invention is directed to the provision of multi-dose, ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements, as well as similar preservative standards (e.g., EP and JP). The compositions include a balance of ingredients that allow for the formation of ophthalmic compositions that include an anionic drug and exhibit desired characteristics such as stability, preservation efficacy, desired pH, desired osmolality, combinations thereof or the like.
    Type: Grant
    Filed: April 14, 2010
    Date of Patent: July 22, 2014
    Assignee: Alcon Research, Ltd.
    Inventor: Bhagwati P. Kabra
  • Patent number: 8778911
    Abstract: A polyamine-depleted food compositions is provided for preparing foods, intended for humans or animals, for preventing or treating heart rate anomalies.
    Type: Grant
    Filed: January 10, 2007
    Date of Patent: July 15, 2014
    Assignee: Universite De Rennes 1
    Inventors: Jacques Moulinoux, Jean-Pie'rre Estebe
  • Patent number: 8778998
    Abstract: The present invention relates to new biphenyl-3-carboxylic acid modulators of beta-3-adrenoceptor activity, pharmaceutical compositions thereof, and methods of use thereof, wherein R1-R23 are independently selected from the group consisting of hydrogen and deuterium; and at least one of R1-R23 is deuterium.
    Type: Grant
    Filed: April 9, 2010
    Date of Patent: July 15, 2014
    Assignee: Auspex Pharmaceuticals, Inc.
    Inventor: Chengzhi Zhang
  • Publication number: 20140178358
    Abstract: The present invention concerns means and methods for predicting the risk of a subject to suffer from liver damage. In particular, it pertains to a method for predicting the risk of a subject to suffer from liver damage caused by acetaminophen comprising determining the amount of putrescine in a blood, serum or plasma sample that has been obtained from the subject after administration of acetaminophen, and comparing the determined amount to a reference, whereby the risk of the subject to suffer from liver damage caused by acetaminophen is predicted. Also provided are devices for carrying out the aforementioned methods.
    Type: Application
    Filed: December 20, 2013
    Publication date: June 26, 2014
    Applicants: The United States of America as represented by the Secretary of Department of Health and Human Servi, Metanomics Health GmbH
    Inventors: Alexander Strigun, Lisette Leonhardt, Dörthe Ahlbory-Dieker, Lisa M. Pence, Richard Beger
  • Publication number: 20140179783
    Abstract: The invention provides an easy-to-drink beverage that contains citrulline, wherein the generation of bad odors due to storage or heating is suppressed. In particular, the invention provides a beverage that contains citrulline, citric acid, sodium citrate, water, and one or more supplements that are saccharides, souring agents, preservatives, colorants, flavoring agents, functional ingredients, or carbon dioxide.
    Type: Application
    Filed: February 7, 2014
    Publication date: June 26, 2014
    Applicant: Kyowa Hakko Bio Co., Ltd.
    Inventors: Yasushi SAKAI, Takeshi IKEDA, Ayako KAMIMURA
  • Publication number: 20140162996
    Abstract: One aspect of the disclosure relates to derivatives of aryl and heterocyclic ureido aryl and heterocyclic carboxamido isobutyric acids, dichlorophenyl urea, curcumin, and 1,3-diazetidine-2,4-dione, and pharmaceutical compositions thereof. The derivatives disclosed herein can modulate development of adipocytes and various cancer cells, including resistant cancer cells and cancer stem cells. Another aspect of the disclosure relates to the use of the derivatives and pharmaceutical compositions disclosed herein in treatment of obesity and various cancers.
    Type: Application
    Filed: July 29, 2013
    Publication date: June 12, 2014
    Applicant: CITY OF HOPE
    Inventors: Samuel RAHBAR, James L. FIGAROLA, Christopher LINCOLN, David HORNE, Rachael MOONEY, Monika POLEWSKI, George SOMLO, Lixin YANG
  • Publication number: 20140135396
    Abstract: The invention is directed to the treatment of patients at risk for liver damage due to the overingestion of acetaminophen by administering agents that increase hepatic levels of nitric oxide.
    Type: Application
    Filed: July 4, 2012
    Publication date: May 15, 2014
    Applicants: BETH ISRAEL DEACONESS MEDICAL CENTER, INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Wolfram Goessling, Andrew Cox, Trista North
  • Publication number: 20140113884
    Abstract: Compounds and compositions comprising epoxyeicosatrienoic acid (EET) analogs that act as EET agonists and are useful as medications in the treatment of drug-induced nephrotoxicity, hypertension and other related conditions. Methods of making and using the compounds and compositions are further described.
    Type: Application
    Filed: April 4, 2012
    Publication date: April 24, 2014
    Inventors: John David Imig, William B. Campell, John Russell Falck
  • Publication number: 20140107085
    Abstract: The invention includes compositions comprising selective AKR1C3 inhibitors. The invention also includes compositions comprising bifunctional AKR1C3 inhibitors and selective androgen receptor modulators. The invention further includes methods of treatment using the compositions of the invention.
    Type: Application
    Filed: October 10, 2013
    Publication date: April 17, 2014
    Applicant: The Trustees of The University of Pennsylvania
    Inventors: Trevor M. Penning, Adegoke O. Adeniji, Michael C. Burns, Jeffrey Winkler, Barry Twenter